Overview

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

Status:
Completed

Trial end date:
2020-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of ustekinumab in pediatric participants aged greater than or equal to (>=) 6 through less than (<) 12 years with moderate to severe chronic plaque psoriasis

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Ustekinumab